AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor gamma (PPARgamma), encoded by the PPARG gene, regulates insulin sensitivity and adipogenesis, and may bind polyunsaturated fatty acids (PUFA) and thiazolidinediones in a ligand-dependent manner. The PPARG proline for alanine substitution at position 12 (Pro12Ala polymorphism) has been related with obesity directly and via interaction with PUFA. METHODS: We tested the effect-modifying role of Pro12Ala on the 1 year change in obesity-related traits in a randomised clinical trial of treatment with metformin (n = 989), troglitazone (n = 363) or lifestyle modification (n = 1,004) vs placebo (n = 1,000) for diabetes prevention in high-risk individuals. RESULTS: At baseline, Ala12 carriers had larger waists (p < 0.001) and, in a subset, more subcutaneous adipose tissue (SAT; lumbar 2/3; p = 0.04) than Pro12 homozygotes. There was a genotype-by-intervention interaction on 1-year weight change (p = 0.01); in the placebo arm, Pro12 homozygotes gained weight and Ala12 carriers lost weight (p = 0.001). In the metformin and lifestyle arms, weight loss occurred across genotypes, but was greatest in Ala12 carriers (p < 0.05). Troglitazone treatment induced weight gain, which tended to be greater in Ala12 carriers (p = 0.08). In the placebo group, SAT (lumbar 2/3, lumbar 4/5) decreased in Ala12 allele carriers, but was unchanged in Pro12 homozygotes (p < or = 0.005). With metformin treatment, SAT decreased independently of genotype. In the lifestyle arm, SAT (lumbar 2/3) reductions occurred across genotypes, but were greater in Ala12 carriers (p = 0.03). A genotype-by-PUFA intake interaction on reduction in visceral fat (lumbar 4/5; p = 0.04) was also observed, which was most evident with metformin treatment (p < 0.001). CONCLUSIONS/ INTERPRETATION: Within the Diabetes Prevention Program, the Ala12 allele influences central obesity, an effect which may differ by treatment group and dietary PUFA intake (ClinicalTrials.gov ID no: NCT00004992).
RCT Entities:
AIMS/HYPOTHESIS: Peroxisome proliferator-activated receptor gamma (PPARgamma), encoded by the PPARG gene, regulates insulin sensitivity and adipogenesis, and may bind polyunsaturated fatty acids (PUFA) and thiazolidinediones in a ligand-dependent manner. The PPARGproline for alanine substitution at position 12 (Pro12Ala polymorphism) has been related with obesity directly and via interaction with PUFA. METHODS: We tested the effect-modifying role of Pro12Ala on the 1 year change in obesity-related traits in a randomised clinical trial of treatment with metformin (n = 989), troglitazone (n = 363) or lifestyle modification (n = 1,004) vs placebo (n = 1,000) for diabetes prevention in high-risk individuals. RESULTS: At baseline, Ala12 carriers had larger waists (p < 0.001) and, in a subset, more subcutaneous adipose tissue (SAT; lumbar 2/3; p = 0.04) than Pro12 homozygotes. There was a genotype-by-intervention interaction on 1-year weight change (p = 0.01); in the placebo arm, Pro12 homozygotes gained weight and Ala12 carriers lost weight (p = 0.001). In the metformin and lifestyle arms, weight loss occurred across genotypes, but was greatest in Ala12 carriers (p < 0.05). Troglitazone treatment induced weight gain, which tended to be greater in Ala12 carriers (p = 0.08). In the placebo group, SAT (lumbar 2/3, lumbar 4/5) decreased in Ala12 allele carriers, but was unchanged in Pro12 homozygotes (p < or = 0.005). With metformin treatment, SAT decreased independently of genotype. In the lifestyle arm, SAT (lumbar 2/3) reductions occurred across genotypes, but were greater in Ala12 carriers (p = 0.03). A genotype-by-PUFA intake interaction on reduction in visceral fat (lumbar 4/5; p = 0.04) was also observed, which was most evident with metformin treatment (p < 0.001). CONCLUSIONS/ INTERPRETATION: Within the Diabetes Prevention Program, the Ala12 allele influences central obesity, an effect which may differ by treatment group and dietary PUFA intake (ClinicalTrials.gov ID no: NCT00004992).
Authors: Z Huang; S E Hankinson; G A Colditz; M J Stampfer; D J Hunter; J E Manson; C H Hennekens; B Rosner; F E Speizer; W C Willett Journal: JAMA Date: 1997-11-05 Impact factor: 56.272
Authors: P W Franks; J Luan; P O Browne; A-H Harding; S O'Rahilly; V K K Chatterjee; N J Wareham Journal: Metabolism Date: 2004-01 Impact factor: 8.694
Authors: Asli Memisoglu; Frank B Hu; Susan E Hankinson; JoAnn E Manson; Immaculata De Vivo; Walter C Willett; David J Hunter Journal: Hum Mol Genet Date: 2003-09-23 Impact factor: 6.150
Authors: Wilfred Y Fujimoto; Kathleen A Jablonski; George A Bray; Andrea Kriska; Elizabeth Barrett-Connor; Steven Haffner; Robert Hanson; James O Hill; Van Hubbard; E Stamm; F Xavier Pi-Sunyer Journal: Diabetes Date: 2007-03-15 Impact factor: 9.461
Authors: Inga Peter; Jeanne M McCaffery; Alyson Kelley-Hedgepeth; Hakon Hakonarson; Steven Reis; Lynne E Wagenknecht; Alan S Kopin; Gondon S Huggins Journal: Obesity (Silver Spring) Date: 2012-02-06 Impact factor: 5.002
Authors: Tao Huang; Tiange Wang; Yoriko Heianza; Yan Zheng; Dianjianyi Sun; Jae H Kang; Louis R Pasquale; Eric B Rimm; JoAnn E Manson; Frank B Hu; Lu Qi Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Mary Helen Black; Jun Wu; Miwa Takayanagi; Nan Wang; Kent D Taylor; Talin Haritunians; Enrique Trigo; Jean M Lawrence; Richard M Watanabe; Thomas A Buchanan; Anny H Xiang Journal: J Clin Endocrinol Metab Date: 2015-01-13 Impact factor: 5.958
Authors: Marta Garaulet; Caren E Smith; Teresa Hernández-González; Yu-Chi Lee; Jose M Ordovás Journal: Mol Nutr Food Res Date: 2011-11-21 Impact factor: 5.914
Authors: Amy L Anderson; Tamara B Harris; Denise K Houston; Frances A Tylavsky; Jung Sun Lee; Deborah E Sellmeyer; Nadine R Sahyoun Journal: Eur J Nutr Date: 2010-02-21 Impact factor: 5.614